Press release
Lawsuit filed for Investors who lost money with shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM)
A lawsuit was filed on behalf of investors in Actinium Pharmaceuticals, Inc. (NYSE: ATNM) shares.
Investors who purchased shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) have certain options and for certain investors are short and strict deadlines running. Deadline: May 26, 2025. NYSE: ATNM investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
New York based Actinium Pharmaceuticals, Inc. Actinium Pharmaceuticals develops targeted radiotherapies, such as Iomab-B, to treat people who have failed existing oncology therapies. Iomab-B is an induction-and-conditioning agent used before bone marrow transplants and has the potential to treat elderly relapsed or refractory acute myeloid leukemia. Actinium evaluated Iomab-B in the pivotal Phase 3 Sierra trial (the "Sierra Trial"), where the drug met the primary endpoint of durable Complete Remission with statistical significance (p
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lawsuit filed for Investors who lost money with shares of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) here
News-ID: 3964113 • Views: …
More Releases from Shareholders Foundation, Inc.
Lawsuit filed for Investors who lost money with shares of Tronox Holdings plc (N …
An investor, who purchased shares of Tronox Holdings plc (NYSE: TROX), filed a lawsuit over alleged violations of Federal Securities Laws by Tronox Holdings plc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Tronox Holdings plc (NYSE: TROX) have certain options and for certain investors are short and strict deadlines running. Deadline: November 3, 2025. NYSE: TROX investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Investigation announced for Investors in Petco Health and Wellness Company, Inc. …
An investigation was announced for current long-term investors in shares of Petco Health and Wellness Company, Inc. (NASDAQ: WOOF) concerning potential breaches of fiduciary duties by certain directors of Petco Health and Wellness Company, Inc.
Investors who are current long term investors in Petco Health and Wellness Company, Inc. (NASDAQ: WOOF) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation…
Investigation announced for Long-Term Investors in RxSight, Inc. (NASDAQ: RXST) …
An investigation was announced for current long-term investors in shares of RxSight, Inc. (NASDAQ: RXST) concerning potential breaches of fiduciary duties by certain directors of RxSight, Inc.
Investors who are current long term investors in RxSight, Inc. (NASDAQ: RXST) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: RXST…
Tesla, Inc. (NASDAQ: TSLA) Investor Alert: Deadline in Lawsuit on October 3, 202 …
A deadline is coming up on October 3, 2025 in the lawsuit filed for certain investors of Tesla, Inc. (NASDAQ: TSLA) over alleged securities laws violations by Tesla, Inc.
Investors who purchased shares of Tesla, Inc. (NASDAQ: TSLA) have certain options and there are strict and short deadlines running. Deadline: October 3, 2025. Tesla, Inc. (NASDAQ: TSLA) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -…
More Releases for Actinium
Hematopoietic Stem Cell Transplantation Market to Reach New Heights in Growth by …
Hematopoietic Stem Cell Transplantation Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Sanofi, Actinium Pharma, Medexus Pharma, medac Pharma, Actinium Pharma
The Hematopoietic Stem Cell Transplantation market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hematopoietic Stem Cell Transplantation pipeline products will significantly revolutionize the Hematopoietic Stem Cell Transplantation market dynamics.
DelveInsight's "Hematopoietic Stem…
How Mobile Technology is Influencing the Actinium Isotope Market
Actinium Isotope Market size was valued at USD 1.2 Billion in 2024 and is forecasted to grow at a CAGR of 8.7% from 2026 to 2033, reaching USD 2.5 Billion by 2033.
Actinium Isotope Market Future Scope
The Actinium Isotope Market was valued at approximately USD 15 million in 2022, with a compound annual growth rate (CAGR) of around 7.5% expected over the forecast period from 2023 to 2030. This market's growth…
Actinium-225 Research:CAGR of 20.6% during the forecast period
QY Research Inc. (Global Market Report Research Publisher) announces the release of 2025 latest report "Actinium-225- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031". Based on current situation and impact historical analysis (2020-2024) and forecast calculations (2025-2031), this report provides a comprehensive analysis of the global Wire Drawing Dies market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global…
Hematopoietic Stem Cell Transplantation Market to Expand Significantly by 2034, …
The Hematopoietic Stem Cell Transplantation market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hematopoietic Stem Cell Transplantation pipeline products will significantly revolutionize the Hematopoietic Stem Cell Transplantation market dynamics.
DelveInsight's "Hematopoietic Stem Cell Transplantation Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Hematopoietic Stem Cell Transplantation, historical and forecasted epidemiology as…
Actinium-225 Market: Size, Share, Growth, Analysis, Key Players, Revenue, | Valu …
Actinium-225 Market Size
The global Actinium-225 market was valued at US$ 0.6 million in 2023 and is anticipated to reach US$ 1.6 million by 2030, witnessing a CAGR of 15.2% during the forecast period 2024-2030.
View sample report
https://reports.valuates.com/request/sample/QYRE-Auto-35M13954/Global_Actinium_225_Market_Research_Report_2023
Actinium-225 Market
Actinium-225 (225Ac, Ac-225) is an isotope of actinium. It undergoes alpha decay to francium-221 with a half-life of 10 days, and is an intermediate decay product in the neptunium series (the decay chain starting…
Hematopoietic Stem Cell Transplantation Market Growth to Accelerate in Forecast …
The Hematopoietic Stem Cell Transplantation market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hematopoietic Stem Cell Transplantation pipeline products will significantly revolutionize the Hematopoietic Stem Cell Transplantation market dynamics.
DelveInsight's "Hematopoietic Stem Cell Transplantation Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Hematopoietic Stem Cell Transplantation, historical and forecasted epidemiology as well as…
